HomeCompareHLTRF vs NOBL

HLTRF vs NOBL: Dividend Comparison 2026

HLTRF yields 66.67% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLTRF wins by $10.6K in total portfolio value
10 years
HLTRF
HLTRF
● Live price
66.67%
Share price
$3.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.5K
Annual income
$11.08
Full HLTRF calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — HLTRF vs NOBL

📍 HLTRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLTRFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLTRF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLTRF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLTRF
Annual income on $10K today (after 15% tax)
$5,666.67/yr
After 10yr DRIP, annual income (after tax)
$9.42/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, NOBL beats the other by $199.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLTRF + NOBL for your $10,000?

HLTRF: 50%NOBL: 50%
100% NOBL50/50100% HLTRF
Portfolio after 10yr
$28.2K
Annual income
$128.63/yr
Blended yield
0.46%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HLTRF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-1.0
Piotroski
5/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLTRF buys
0
NOBL buys
0
No recent congressional trades found for HLTRF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLTRFNOBL
Forward yield66.67%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$33.5K$22.8K
Annual income after 10y$11.08$246.19
Total dividends collected$8.1K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HLTRF vs NOBL ($10,000, DRIP)

YearHLTRF PortfolioHLTRF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$14,033$3,333.33$10,914$214.34+$3.1KHLTRF
2$17,202$2,185.88$11,897$218.63+$5.3KHLTRF
3$19,658$1,252.04$12,952$222.72+$6.7KHLTRF
4$21,702$668.61$14,086$226.62+$7.6KHLTRF
5$23,566$344.93$15,302$230.33+$8.3KHLTRF
6$25,391$175.03$16,607$233.85+$8.8KHLTRF
7$27,257$88.12$18,007$237.18+$9.3KHLTRF
8$29,209$44.20$19,508$240.35+$9.7KHLTRF
9$31,276$22.14$21,116$243.35+$10.2KHLTRF
10$33,476$11.08$22,841$246.19+$10.6KHLTRF

HLTRF vs NOBL: Complete Analysis 2026

HLTRFStock

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

Full HLTRF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this HLTRF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLTRF vs SCHDHLTRF vs JEPIHLTRF vs OHLTRF vs KOHLTRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.